Cited by Helix-based screening with structure prediction using artificial intelligence has potential for the rapid development of peptide inhibitors targeting class I viral fusion

Efficient inhibition of SARS-CoV-2 emerging EG.5, EG.5.1 and BA.2.86 variants by fusion inhibitor HY3000 peptide DOI

Lili Wu, Anqi Zheng,

Yangming Tang

et al.

hLife, Journal Year: 2023, Volume and Issue: 2(1), P. 43 - 46

Published: Oct. 12, 2023

Language: Английский

Citations

Chemically modified antiviral peptides against SARS‐CoV‐2 DOI

Michael Quagliata, Anna Maria Papini, Paolo Rovero

et al.

Journal of Peptide Science, Journal Year: 2023, Volume and Issue: unknown

Published: Sept. 12, 2023

To date, the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) COVID‐19 pandemic continues to be a potentially lethal disease. Although both vaccines and specific antiviral drugs have been approved, search for more therapeutic approaches is still ongoing. The infection mechanism of SARS‐CoV‐2 consists several stages, each one can selectively blocked disrupt viral infection. Peptides are promising class compounds, which may suitably modified stable, effective, selective towards replication step. latter two goals might obtained by increasing specificity and/or affinity interaction with target often imply stabilization secondary structure active peptide. This review focused on peptides against acting at different stages virus replication, including ACE2‐RBD interaction, membrane fusion mechanism, proteolytic cleavage proteases. Therefore, landscape presented herein provides useful springboard design new powerful therapeutics.

Language: Английский

Citations

A New Chimeric Antibody against the HIV-1 Fusion Inhibitory Peptide MT-C34 with a High Affinity and Fc-Mediated Cellular Cytotoxicity DOI

С. В. Калиниченко, Lama Ramadan, Natalia Kruglova

et al.

Biology, Journal Year: 2024, Volume and Issue: 13(9), P. 675 - 675

Published: Aug. 29, 2024

Peptides from heptad repeat (HR1 and HR2) regions of gp41 are effective inhibitors HIV-1 entry that block the fusion viral cellular membranes, but generation antibodies highly specific for these peptides is challenging. We have previously described a mouse hybridoma recognizes MT-C34-related derived HR2. It was used selection HIV-1-resistant CD4 lymphocytes engineered to express MT-C34 peptide via CRISPR/Cas9-mediated knock-in into CXCR4 locus. In this study, we cloned variable domains antibody generated recombinant chimeric (chAb) by combining it with constant humanized Trastuzumab. The new chAb displayed high specificity two-fold higher level affinity than parental monoclonal antibody. addition, mediated up 27–43% antibody-dependent cytotoxicity towards cells expressing on their surface. anti-MT-C34 can be easily using plasmids available research community serve as valuable tool detection, purification, even subsequent elimination or CAR fight infection.

Language: Английский

Citations

Multidisciplinary examples of applications: Papers using the MAL-PD/BD/CI/BI theory/method DOI

Ting-Chao Chou

Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 181 - 218

Published: Jan. 1, 2024

Language: Английский

Citations

The role of N-terminal acetylation of COVID fusion peptides in the interactions with liquid-ordered lipid bilayers DOI

Izabela Miłogrodzka, Anton P. Le Brun, Mark M. Banaszak Holl

et al.

Journal of Colloid and Interface Science, Journal Year: 2024, Volume and Issue: 679, P. 446 - 456

Published: Oct. 21, 2024

Language: Английский

Citations

Development of lipopeptide-based HIV-1/2 fusion inhibitors targeting the gp41 pocket site with a new design strategy DOI

Xiuzhu Geng,

Yuanmei Zhu,

Gao Yue

et al.

Antiviral Research, Journal Year: 2024, Volume and Issue: unknown, P. 106042 - 106042

Published: Nov. 1, 2024

Language: Английский

Citations

Efficient inhibition of fusion inhibitor HY3000 peptide to SARS-CoV-2 emerging EG.5, EG.5.1 and BA.2.86 variants DOI

Lili Wu, Anqi Zheng,

Yangming Tang

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: Sept. 28, 2023

Abstract SARS-CoV-2 continues to evolve and spread. Recently, the Omicron EG.5 lineage, bearing an additional F456L mutation in spike (S) protein compared its ancestor XBB.1.9.2, sub-variant EG.5.1, which carries a further Q52H mutation, have raised concerns due their increased prevalence extended immune escape properties. Additionally, alarming variant, BA.2.86, has also garnered global concern because it contains over 30 amino acid mutations S BA.2, including more than 10 changes receptor-binding domain (RBD), reminiscent of appearance variant late 2021. Therefore, there is urgent need assess effectiveness current vaccines therapeutics against EG.5, EG.5.1 BA.2.86. In our previous work, we reported design broad-spectrum antiviral activity peptide fusion inhibitor HY3000 variants XBB.1.5. Here, continued evaluate inhibitory potency prevailing as well XBB.1.16, FL.1.5.1, FY.3 Our data indicated that retained potent activities these variants, indicating potential good virus with therapeutic effect future variants. Currently, been finished Phase II clinical trial China approved conduct investigation by U.S. Food Drug Administration (FDA), suggesting application prospect ongoing COVID-19.

Language: Английский

Citations

Helix-based screening with structure prediction using artificial intelligence has potential for the rapid development of peptide inhibitors targeting class I viral fusion DOI

Satoshi Suzuki,

Mio Kuroda,

Keisuke Aoki

et al.

RSC Chemical Biology, Journal Year: 2023, Volume and Issue: 5(2), P. 131 - 140

Published: Nov. 7, 2023

Peptide inhibitors against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are designed using a screening system for peptide-based containing an α-helix region (SPICA) and structures predicted by AlphaFold2.

Language: Английский

Citations